United Therapeutics (NASDAQ:UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Equal-weighted exchange-traded funds (ETFs) invest equal amounts in businesses irrespective of their market capitalizations. Conversely, a cap-weighted index, allows companies with...
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.